For specific results, we calculated family member threats (RR) or chances ratios (OR) in addition to their 95% CI. In cases where considerable heterogeneity was recognized-- I2 > 60% or χ2 P retatrutide dosing schedule</a> in obese patients with or without diabetes. Early tests of retatrutide revealed that users could shed up to a quarter of their body weight in under a year, making it nearly twice as effective as Ozempic.